For example, combination therapy with bevacizumab and CCL2 inhibitor, mNOX-E36, decreased the recruitment of TAMs and angiogenesis, resulted in decreased tumor volume and blood volume in CCL2-expressing rat glioblastoma multiforme model [236]. Here, CCL2 is linked to neoplasm.